Combined retinal vascular occlusion: Demography, clinical features, visual outcome, systemic co-morbidities, and literature review

Vishal Raval, Sameera Nayak, Merlin Saldanha, Subhadrab Jalali, Rajeev Reddy Pappuru, Raja Narayanan, Taraprasad Das

Purpose: To document the clinical features, systemic association, and treatment outcome of patients with a combined retinal vein and artery occlusion (CRVOA) and review of literature. Methods: A retrospective chart review of patients diagnosed with CRVOA at a tertiary eye care center. Patient’s demographic details and associated ocular and systemic factors were recorded. Treatment included laser photocoagulation, anti-vascular endothelial growth factor (VEGF) intravitreal injection or transscleral cyclophotocoagulation (TSCP), alone or in combination. At last, follow-up treatment response was measured in visual acuity status, regression of neovascularization, and control of intraocular pressure (IOP). All cases reported in the current decade were analyzed and compared with this study. Results: Seventeen eyes with CRVOA accounted for 0.3% of total vascular occlusion (total 5151 patients were seen in this period). The mean age was 48.12 ± 17.5 years (range: 12-87 years) and there were 9 females. Nine eyes had CRVO + CRAO; 6 eyes had BRVO + BRAO, and one patient each had CRVO + BRAO and CRAO + BRVO. Fluorescein angiography (FA) showed delayed ‘arm to retina’ time (>20 seconds) in all 10 eyes and delayed arteriovenous transit time in 9 out of 10 eyes. Optical coherence tomography (OCT) showed hyporeflective inner retinal layers (16 eyes) and neurosensory detachment (7 eyes). The most common systemic associations were hypertension and dyslipidemia (n = 7 people; 41.18%) each. Four patients (23.5%) had a plaque in carotid arteries with normal 2D echocardiography. Ten (59%) eyes were treated with intravitreal bevacizumab + laser; four (23.5%) eyes were treated with laser only, and three (17.6%) eyes were treated with laser + anti-VEGF + TSCP. At last follow up, vision improved in 9 (52.9%) eyes; stable in 3 (17.7%) eyes, and reduced to perception of light in 5 (29.4%) eyes. Conclusion: Combined CVRVOA is a rare emergency leading to acute vision loss. Early diagnosis and treatment for ocular complications and systemic evaluation for cardiovascular risk factors are needed.

Key words: Cardiovascular factors, combined retinal artery and vein occlusion, intravitreal bevacizumab, laser photocoagulation

Combined retinal vascular occlusions involving the vein and the artery is a rare event. Traditionally, the retinal vein occlusions are classified into branch retinal vein occlusion (BRVO), macular vein occlusion, central retinal vein occlusion (CRVO), and hemi central retinal vein occlusion (HCRVO); the retinal artery occlusions are classified into central retinal artery occlusion (CRAO), branch retinal artery occlusion (BRAO), and cilioretinal artery occlusion (CLRRAO). The combined vein and artery occlusion could be any permutation and combination such as CRVO + CRAO, CRVO + BRAO, BRVO + CRAO, and BRVO + BRAO.[1‑3] Majority of patients suffer from CRVO + CRAO, and occasionally with CLRRAO or BRAO.[4,5] The less common reported entity is BRVO + BRAO.[6] A variety of pathological mechanisms are described for these combined occlusions. A sudden increase in intraluminal retinal capillary bed pressure secondary to CRVO could lead to CLRRAO.[7] Similarly reduction in perfusion pressure of the cilioretinal and retinal arteries, in turn, leads to decreased retinal circulation and subsequent venous stasis and thrombosis. Many systemic co-morbidies associated with retinal vein occlusions—atherosclerosis, hypertension, hyperlipidemia, diabetes, and hyperhomocysteinemia in people aged above 50 years[6] and thrombophilic disorders, hyperviscosity blood disorders, systemic vasculitis, and autoimmune diseases in people aged less than 40 years[9] — could damage the adjacent artery to cause combined vascular occlusion. The commonly reported systemic associations are diabetes, hypertension, and dyslipidemia.[10,11]

In general, the prognosis of patients with combined vascular occlusion is poor. Majority of the eyes develop severe complications, such as rubeosis iridis and neovascular glaucoma.[12,13] Therefore, early diagnosis and intervention are needed.[6] Considering the rare nature of the disease and very

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

Cite this article as: Raval V, Nayak S, Saldanha M, Jalali S, Pappuru RR, Narayanan R, et al. Combined retinal vascular occlusion: Demography, clinical features, visual outcome, systemic co-morbidities, and literature review. Indian J Ophthalmol 2020;68:2136-42.
few anecdotal case reports,[1‑4] and short case series[9] published in the literature, the current understanding of this disease is very limited. This article describes the clinical profile, imaging features, associated systemic co-morbidities, complications and visual outcomes in patients of the combined retinal vein and artery occlusion (CRVOA). This article has also compiled the reports of combined vascular occlusion in this decade and compared it with the present series.

Methods

In a retrospective chart review of all patients diagnosed with combined retinal vein and retinal artery occlusion between January 2016 and December 2018 at a tertiary eye care institute were included. We used electronic medical records to get ICD coding for both retinal artery (H 34.1) as well as retinal vein occlusion (H 34. 2 and H 34.8) to identify our study population. The diagnosis was made by clinical examination and specific retinal investigations. Inclusion criteria included patients who were diagnosed to have acute and recent onset of combined vascular occlusion. We excluded cases who presented with sequential or late-onset of combined vascular occlusion. Patients with ocular ischemic syndrome, diabetic retinopathy, hypertensive retinopathy, and other co-existing ocular disorders were also excluded from the study. Informed consent was obtained from all patients and the study was approved by the institutional ethics committee. The study adhered to the tenets of the Declaration of Helsinki of medical research involving human subjects.

Demographic details like age at presentation, sex, eye involved, and types of occlusion were recorded. The patients were categorized into two age groups: group 1 below 40 years and group 2 above 40 years. A thorough review of the patient’s medical chart was made at baseline and at every follow-up visit. It included presenting and best-corrected visual acuity, anterior segment examination including the presence of iris neovascularization (NVI), measurement of intraocular pressure (IOP) by Goldmann applanation tonometer, gonioscopy, and a dilated fundus examination. Special ophthalmic examinations included fluorescein angiography (FA) and optical coherence tomography (OCT). FA recorded the arm-to-retina time (in seconds), the distribution of capillary nonperfusion (CNP) areas and presence of new vessels elsewhere (NVE) on the retina, new vessels on disc (NVD), new vessels on iris (NVI), and cystoid macular edema (CME). OCT documented the presence of hyperreflective nerve fiber layer; this confirms the occurrence of arterial occlusion even in the presence of significant retinal hemorrhages secondary to vein occlusion. The macular cube OCT qualified and quantified macular edema, when present. A detailed systemic examination by an internist documented systemic disease, if any. Pertinent personal history such as cigarette smoking was noted. Blood pressure was measured using a manual sphygmomanometer in a sitting position. Blood investigations included complete blood count, fasting and postprandial blood sugar, complete lipid profile, renal profile, coagulation profile, and serum homocysteine were performed in all patients as per the institution protocol for all vascular disease. Autoimmune disease workup was ordered in all people aged below 40 years. Systemic investigations also included carotid doppler ultrasonography, and 2D echocardiology. Patients with either carotid artery disease or abnormal echocardiology were referred to cardiologist for further evaluation. In subsequent follow-up visits search was made for NVE, NVD, NVI, and neovascular glaucoma (NVG). NVG was diagnosed by the presence of NVI and new vessels in angle (NVA) leading to secondary open or closed-angle associated with elevated IOP (>21 mm Hg) in the presence of posterior segment ischemia.

Eyes that had either cystoid macular edema or ocular neovascularization in form of NVI, NVA, or NVE at the time of presentation were appropriately treated with laser photoacoagulation (PHC) and/or intravitreal anti-vascular endothelial growth factor (VEGF) therapy where visual potential existed, and transscleral diode laser cyclophotocoagulation (TSCPC)/cyclocryotherapy when the visual potential did not exist.

All patients were followed up for a minimum duration of 3 months and essential outcome parameters were recorded, such as improvement (2 or more Snellen’s line) or stabilization of vision, and IOP. All complications, either secondary to disease or treatment per se, were also recorded.

Literature review for all the CRVOA cases based on a PUBMED database search, using the terms combined retinal vascular occlusion, central retina artery and vein occlusion, and branch retinal artery and vein occlusion in the current decade (2009-2018) were reviewed and compared with our study.

Results

In the study period of 3 years, 5151 people were treated in the institute for retinal vascular occlusion. This included 4377 (85%) people with vein occlusion and 774 (15%) people with artery occlusion. In the study period, 17 patients (17 eyes) were diagnosed to have combined retinal artery and vein occlusion; this study included these consecutive patients. This was 0.3% of all retinal vascular occlusion in this period and consisted of CRVO + CRAO in 9 patients [Fig. 1- Case 2], BRVO + BRAO in 6 patients [Fig. 2- Case 6], CRVO + BRAO in one patient and BRVO + CRAO in one patient. Cilioretinal artery occlusion was not seen in any patients (confirmed on FA). The mean age of the patients was 48.12 ± 17.5 years (Interquartile range: 35.5-56.2 years, range: 12-87 years), there were 9 females, and the left eye was affected in 12 (70.6%) patients. Twelve patients were aged above 40 years and 5 people were under 40 years. At presentation, IOP was greater than 21 mm Hg in 2 (11.7%) eyes. The super temporal quadrant vessels, both vein and artery, were involved in 5 of 6 eyes in combined BRVO and BRAO occlusions. Three eyes had cystoid macular edema (2 eyes with BRVO + BRAO and one eye with CRVO + CRAO). In all patients, the other eye was normal with mild hypertensive changes. The presenting best-corrected visual acuity was ≤ 20/200 in 13 patients. In 3 months follow up, 10 eyes developed ocular neovascularization as follows: NVI in 6 eyes and NVD + NV in 4 eyes. Thirty eyes received intravitreal bevacizumab injection, 10 eyes with ocular neovascularization, and 3 eyes with cystoid macular edema. Finally, 7 eyes developed NVG and 2 eyes developed vitreous hemorrhage. The mean duration of follow-up was 11 months (range 3-24 months). The complete demographic and clinical details are shown in Table 1.
On FA (10 eyes), there was delayed arm to retina time (>20 seconds) in all 10 eyes, delayed arteriovenous (AV) transit time in 9 eyes, and presence of 2 or more quadrant CNP areas in 10 eyes. OCT showed hype reflective inner retinal layers in 16 eyes, neurosensory detachment in 7 eyes, macular edema in 3 eyes, and inner retinal layer atrophy in one eye.

On systemic evaluation, 7 (41.8%) people each had hypertension and dyslipidemia, 4 (23.5%) people each had diabetes mellitus and hyperhomocysteinemia, and 1 person (case no-11, age 12 years) had autoimmune disease (lupus coagulopathy) associated with thrombosis. In patients less than 40 years of age \( (n = 5; \text{CRVO + CRAO}) \), there was anemia with leucopenia \( (n = 2) \), anemia with thrombocytopenia \( (n = 1) \), antiphospholipid antibody syndrome \( (n = 1) \), and dyslipidemia \( (n = 1) \). On carotid doppler ultrasonography, 4 people showed plaque formation on the same side of occlusion (2 fibro-fatty plaque and 2 calcific plaque in carotid artery) with stenosis in internal carotid or common carotid artery ranging from (22% to 51%); 2 D echocardiography didn’t show vegetation or embolic material on any of heart valves. In 3 patients ocular or systemic risk factors could not be identified despite complete blood investigations and multimodal imaging. Two of the 3 eyes had NVD and NVE and in both of them, vision did not improve after treatment.

The treatment in the current cohort consisted of combination of intravitreal anti VEGF (bevacizumab 1.25 mg in 0.05 ml) with pan retinal photocoagulation (PRP) in 7 (41%) eyes for regression of NVD/NVE; anti VEGF with sectoral laser PHC in 3 eyes (17%) for associated macular edema; sectoral laser PHC alone in 4 (24%) eyes, and combination of laser, anti-VEGF and TSCP in 3 (17%) eyes. Three eyes that had gross CNP areas, but no NVE or macular edema, were still treated with retinal laser to prevent development of retinal new vessels as suggested in one earlier report from India.[6] At the last follow up, the best corrected visual acuity showed improvement of 2 or more Snellen’s line in 9 (52.9%) patients; remained stable in 3 (17.7%) patients, and reduced to perception of light in 5 (29.4%) patients [Table 1].

In this decade, 2009-2018 a total of 41 cases are reported; this consists of 3 case series \(^6^{,10,11}\) and 17 case reports\(^{14-28}\) of CRVAO published in English language (PubMed search). In the isolated case reports of 17 patients, the mean patient age was
| #   | Age/Sex  | Eye | Syst Dis | Carotid Doppler | Occlusion type | Eye at presentation | Treatment | At Last Follow up | FU (months) | Fellow Eye |
|-----|----------|-----|----------|-----------------|----------------|-------------------|------------|------------------|-------------|------------|
| 1   | 52/M     | LE  | HTN      | Left side atheromatous thickening with calcific plaque | CRVO + BRAO     | CF1M               | 19 YES, NVI | YES              | NO          | TSCPC      |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
| 2   | 34/F     | LE  | C        | NORMAL           | CRVO + CRAO WITH CLIORETINAL SPARING | HM                  | 12 YES, NVE | YES              | NO          | CFCF       |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
| 3   | 31/F     | LE  | C        | NORMAL           | CRVO + CRAO     | PL PR Acc          | 13 YES, NVI, NVD | --              | YES         | Sc LASER   |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
| 4   | 67/M     | LE  | DM       | Minimal hyperplasia with fibrotatty plaque | CRVO + CRAO     | OF1 M               | 50 YES, NVI | 32 sec           | NO          | CFCF       |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
| 5   | 54/M     | LE  | DM, HTN  | NORMAL           | STQ BRVO + BRAO | OF 1 M              | 14 YES, NVE | 20 sec           | YES         | Sc LASER   |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
| 6   | 46/M     | LE  | HTN      | NORMAL           | STQ BRVO + BRAO | 20/40               | 10 NO      | 21 sec           | NO          | Sc LASER   |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
| 7   | 52/F     | LE  | -        | NORMAL           | ITQ BRVO + BRAO | 20/400              | 16 NO      | 20 sec           | NO          | Sc LASER   |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
| 8   | 87/F     | RE  | -        | NORMAL           | ITQ BRVO + CRAO + GLAUCOMA | 20/80               | 11 NO      | --              | YES, NVD    | Sc LASER   |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
| 9   | 45/F     | RE  | D        | NORMAL           | CRAO + CRVO     | CF1M               | 14 NO      | --              | YES, NVD    | TSCPC + ARC |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
| 10  | 28/F     | LE  | C        | NORMAL           | CRAO + CRVO     | HM                  | 11 YES, NVI | 22 sec           | NO          | Sc LASER   |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
| 11  | 12/M     | LE  | Lupus coagulopathy | NORMAL         | CRAO + CRVO     | CFCF               | 17 YES, NVI | --              | YES, NVD    | Sc LASER   |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
| 12  | 47/M     | RE  | HTN, D, HH| NORMAL          | STQ BRVO + BRAO | 20/30              | 14 NO      | 20 sec           | NO          | Sc LASER   |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
| 13  | 36/M     | LE  | D, HH    | NORMAL           | CRAO + CRVO     | 20/200             | 16 NO      | --              | YES, Cherry red spot | Sc LASER   |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
| 14  | 67/F     | RE  | DM, HTN, D| Intraluminal eccentric fibrotatty plaque in RT proximal common carotid | CRAO + CRVO     | PL PR Inacc         | 42 YES, NVG | 20 sec           | NO          | Sc LASER   |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
| 15  | 63/F     | LE  | DM, HTN, D| CALCIFIC PLAQUES | CRAO + CRVO     | PL PR Inacc         | 30 YES, NVI | --              | YES         | Sc LASER   |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
| 16  | 52/F     | LE  | D, HH    | NORMAL           | STQ BRVO + BRAO | 20/320             | 13 YES, NVD | --              | YES, NVD    | Sc LASER   |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
| 17  | 45/M     | RE  | HTN, D, HH| NORMAL          | STQ BRVO + BRAO | 20/25              | 10 NO      | 18 sec           | NO          | Sc LASER   |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |
|     |          |     |          |                  |                |                   |            |                  |             |            |

ARC: Anterir Retinal Cryotherapy, Acc: Accurate, BCVA: Best corrected visual acuity, C: Coagulation disorder, CF1M: Counting fingers at 1 metre, CFCF: Counting fingers close to face, CME: Cystoid macular edema, DM: Diabetes mellitus, D: Dyslipidaemia, F: Female, HH: Hyperhomocysteinemia, HM: Hand movement, ITQ: Inferotemporal quadrant, Inacc: Inaccurate, LE: Left eye, M: Male, N: Normal, NAAION: NonArteritic Anterior Ischemic Optic Neuropathy, NPL: Non-perception of light, N: Nasal, NAAION: NonArteritic Anterior Ischemic Optic Neuropathy, NPL: Non-perception of light and says, PRP: Pan retinal photocoagulation, STQ: Superotemporal quadrant, Sc LASER: Sectoral LASER, TSCPC: Transcleral diode photocoagulation, VEGF: Vascular endothelial growth factor.
Table 2: Summary of published CRVAO reports from 2009-2019

| No eyes | Type (n) | Av age (range) | M/F | Systemic risk factors | Presenting VA (<20/400) | Treatment | Complications | Post Rx VA |
|---------|----------|----------------|-----|-----------------------|-------------------------|-----------|---------------|------------|
| **Case Reports**[14-20] |
| 17 | BRVO + BRAO (n=3) | 39.6 (27-54) | 3:0 | Toxoplasmosis, Peripapillary arterial loop, Hyperhomocysteinemia | 02 | Anti-toxo treatment and oral steroids | Retinal atrophy (1) NVG (1) | >20/200=02 Improvement |
| | CRVO + BRAO (n=2) | 41 (16-66) | 0:2 | Hyperhomocysteinemia | 01 | Oral steroids + PRP (1) | NVG (1) | >20/200=0 worsened |
| | CRVO + CRAO (n=6) | 43.6 (3-72) | 1.5 | Chronic renal failure, Factor V mutation, Nephrotic syndrome, Persistent hyaloid artery, Protein C deficiency, Systemic lupus erythematosus | 06 | Oral steroids (1) Anticoagulants (2) | NVG (1) Optic atrophy (1) | >20/200=02 |
| | CLRAO + CRVO (n=6) | 24.1 (9-45) | 4.2 | Sturge Weber Syndrome, Sleep apnea syndrome, HELLP syndrome, Hyperhomocysteinemia, Juvenile glaucoma, Post-partum | 01 | AGM (1) Trabeculectomy (1) | NA | >20/200=04 Improvement |
| **Case Series**[6,10,11] |
| 24 | BRVO + BRAO (n=6) | 54 (39-60) | 5:1 | Dyslipidemia (5), Hypertension (4), Diabetes (4), Hyperhomocysteinemia (1) | 04 | Laser PRP (6), PRP + Avastin (3) | CME (2 eyes), Macular ischemia (2 eyes) NVD/ NVE (2 eyes), TRD (1 eye) | >20/200=04 Improvement (4) Stable (2) |
| | CRVO + BRAO (n=3) | 48.3 (33-64) | 2:1 | Hypertension (2), Chronic smoker (2), Coagulation disorder (1) | 03 | Anticoagulants (1) Antihypertensive (2) | NA | >20/200=01 Improvement (1) Stable (2) |
| | CRVO + CRAO (n=10) | 62 (36-75) | 6:4 | Hypertension (6), Coagulation disorders (5), Dyslipidemia (3), Hyperhomocysteinemia (2) | 10 | Anticoagulants, hemodilution Vitrectomy (1) | NA | >20/200=06 Improvement (6) Stable (3) Worsened (1) |
| | CLRAO + CRVO (n=5) | 41.4 (3-82) | 4:1 | Hypertension (3), Smoking (3) Dyslipidemia (2), Hyperhomocysteinemia (1) | 03 | Low molecular heparin and acetylsalicylic acid (5) | NA | >20/200=01 Not mention in 4 eyes |
| **Present series** |
| 17 | BRVO + BRAO (n=6) | 49.3 (45-54) | 4:2 | Hypertension (4), Dyslipidemia (3), Hyperhomocysteinemia (3) | 03 | Avastin+PRP (4) Sectoral laser (2) | CME (3) NVE (1) NVG (1) | >20/200=06 Improvement (5) Stable (1) |
| | CRVO + BRAO (n=1) | 52 | 1:0 | Hypertension, Carotid: calcific plaques | HM+ | PRP+TSCPC | NVE, NVG | PL=Worsened |
| | CRVO + CRAO (n=9) | 42.5 (12-67) | 3:6 | Dyslipidemia (4), Hypertension (2), Diabetes (3), Coagulation disorders (3) Carotid: fibro fatty plaque (2) and calcific plaque (1) | 08 | PRP + Avastin (6) Sec laser (1) PRP + Avastin + TSCPC (2) | NV (5) NVG (1) Vit hemorrhage (1) | >20/200=02 Improvement (2) Worsened (7) |
| | BRVO + CRAO (n=1) | 87 | 0:1 | Primary open angle glaucoma | 20/80 | Sectoral laser | NVG | PL=Worsened |
35.7 years (range 3-72 years) and the most common occurrences were of CRVO + CRAO (n = 6) and CLRAO + CRVO (n = 6) with a variety of systemic disorders known to cause CRVAO [Table 2]. In the case series of 24 patients the average age was 54.3 years, and the leading systemic associations were hypertension (n = 15) and dyslipidaemia (n = 10). The presenting vision was poor (VA ≤20/400) in 30 of 41 (73%) patients. The management consisted of systemic and ocular treatment: systemic antihypertensive, anticoagulants and ocular- laser photocoagulation and/or intravitreal anti-VEGF injection. At the final follow up vision improved in only 30% cases (n = 20) and remained stable in other half of the patients [Table 2].

**Discussion**

In our series, the patients presented with 4 different types of CRVAOs: CRVO with CRAO, CRVO with BRAO, BRVO with BRAO and CRAO with BRVO. Most patients (n = 12; 70%) in this cohort were aged above 40 years.

Combined arterial and venous blockage is reported to occur in both young and old people and many of them with systemic comorbidities.[8] The important systemic association reported with CRAO are advanced age, hypertension, hyperlipidemia, diabetes, and glaucoma in the older age group (≥40 years),[8] and inherited and acquired coagulation disorders and hyperviscosity syndrome-related factors in younger age group (<40 years).[8] All these conditions generate one or other factors of Virchow’s triad—hypercoagulability, damage to the vessel endothelium, and hamodynamic changes such as venous stasis or turbulence. These features ultimately contribute to venous thrombosis formation thereby causing arterial obstruction by back pressure leading to combined arterial and venous occlusion.[7] In majority of cases in the elderly population, retinal vein occlusion is the primary pathology. Due to atherosclerotic changes in the arteries, the vein gets compressed usually at arteriovenous crossing leading to turbulent blood flow and dynamic obstruction or actual thrombus formation and mechanical blockage. The increased intravascular pressure may cause back pressure to the arterial circulation leading to artery occlusion.[8]

In 4 of our elderly patients, the carotid doppler showed the presence of plaque and one of the other risk factors such as hypertension, diabetes, or dyslipidemia. All these 4 patients had NVI or NVE at follow up visit and despite laser and/or anti-VEGF therapy all eyes had a poor vision (less than hand movements) on the last visit. This was in contrast to 7 other patients who also had systemic diseases (hypertension, diabetes or dyslipidaemia) but did not have pre-existing plaque at carotid doppler; in these patients, vision either improved (n = 6) or remained stable (n = 1) following laser and/or anti-VEGF therapy. Thus, the combination of plaque on carotid and advanced age could be considered a bad prognostic indicator for visual acuity.

In the younger age group, coagulation disorders like anticoagulopin syndrome, von Willebrand syndrome, protein S deficiency, or Factor V mutation are known risk factors for combined occlusion.[22,29] The postulated mechanism is that the hypercoagulable blood state predisposes to venous thrombosis and increased back pressure to the arterial circulation leads to artery occlusion. In our series 2 patients had hyperviscosity related disease, both in their 30s while one young child age 12 years (case no-11) was diagnosed to have lupus coagulopathy with thrombosis. Both of them received anti-VEGF injection with sectoral laser PHC and at the last follow up the new vessels regressed, confirmed by fluorescein angiography. It appears that younger people with hyperviscosity related disease have a better visual prognosis than the older patients with arterial plaques.

One elderly patient had pre-existing advanced primary open-angle glaucoma. Despite laser treatment, the IOP remained uncontrolled and vision was poor at the last follow-up visit. The postulated mechanism is either the rise in the IOP above the mean blood pressure or the fall in blood pressure below the IOP leads to decrease retinal blood flow in the artery, and consequently occurrence of transient CRAO[7] that typically lasts for several hours, mostly during sleep due to marked nocturnal arterial hypotension.

In 3 patients, ocular or systemic risk factors could not be identified despite complete blood investigations and multimodal imaging. The occurrence of CRVAO is also reported in otherwise healthy subjects[30,31] although we suspect that some of these patients in the reported series may not have undergone complete diagnostic tests including transosophageal echocardiography, cerebral magnetic resonance imaging (MRI), and thrombophilia screening. Thus, it is important to consider uncommon (e.g., Flammer syndrome) or common but so far unrecognized (e.g., fluctuation of blood pressure) risk factors for CRVAO in such people.[31]

Typically, eyes with CRVAO have a poor visual outcome and tend to develop complications like NVI and NVG[9] and if untreated, could lead to complete blindness.[9] The ongoing activity of neovascularization due to continuous hypoxia from occlusion and increasing VEGF levels in the vitreous cavity remains the cornerstone for the complications. In our study, 10 (58.8%) eyes had complications like vitreous hemorrhage (2 eyes), NVD (2 eyes), NVE (2 eyes), NVI (6 eyes), and NVG (7 eyes).

The current standards of care in CRVAO are anti-VEGF and laser photocoagulation, often in combination and occasionally TSCP when other treatment fails to prevent NVG.[32] Intravitreal anti-VEGF reduces the VEGF levels and laser PHC reduces retinal ischemia. In our cohort of people, vision either improved or remained stable in 2/3rd of eyes and vision deteriorated in 1/3rd of eyes. Therefore, treatment must be instituted as soon as the diagnosis is made.

The analysis of 41 published cases in this decade [Table 2] showed that the incidence of CRVAO is rarer than isolated retinal vascular occlusion, the occurrence is usually acute, there is significant vision loss at presentation, and the treatment benefit is maximized with early management including care for systemic commodities. The analysis further showed that the people with CRVAO were younger than isolated vein occlusion (average 45.6 years versus average 60 years)[33] and the risk of NVG is higher than the isolated artery or vein occlusions (50% versus less than 20%).[34,35]

**Conclusion**

To summarize, CRVAO is an ocular emergency presenting with painless sudden visual loss. Clinical examination supplemented with Fundus fluorescein angiography (FFA) and OCT help in confirming the diagnosis. A thorough
systemic evaluation is mandatory to look for atherosclerosis, hypertension, dyslipidemia, and diabetes in the elderly people and coagulation and hyperviscosity syndrome in younger people. In majority of instances, ocular neovascularization occurs that must be treated with laser photocoagulation and intravitreal anti-VEGF injection alone or in combination, and occasionally TSCPC for control of glaucoma. Therefore, an early diagnosis, adequate treatment, and timely referral to internist/cardioologist to rule out high-risk factors could help salvage vision in many of these eyes.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References
1. Richards RD. Simultaneous occlusion of the central retinal artery and vein. Trans Am Ophthalmol Soc 1979;77:191-209.
2. Brown GC, Duker JS, Lehman R, Eagle RC Jr. Combined central retinal artery-central vein obstruction. Int Ophthalmol 1993;17:9-17.
3. Shukla D, Arora A, Hadi KM, Kumar M, Baddela S, Kim R. Combined central retinal artery and vein occlusion secondary to systemic non-Hodgkin’s lymphoma. Indian J Ophthalmol 2006;54:204-6.
4. Ozturk T, Takes O, Saatci AO. Dexamethasone implant (ozurdex) in a case with unilateral simultaneous central retinal vein and branch retinal artery occlusion. Case Rep Ophthalmol 2015;6:76-81.
5. Karapetyan A, Ouyang P, Tang LS, Zeng J, Ying MD. Detection of underdiagnosed concurrent branch retinal artery occlusion in a patient with central retinal vein occlusion using spectral domain optical coherence tomography. BMC Ophthalmol 2014;14:91.
6. Sengupta S, Pan U. Combined branch retinal vein and branch retinal artery occlusion-clinical features, systemic associations, and outcomes. Indian J Ophthalmol 2017;65:238-41.
7. Hayreh SS. Acute retinal arterial occlusive disorders. Prog Retin Eye Res 2011;30:59-94.
8. Kolar P. Risk factors for central and branch retinal vein occlusion: A meta-analysis of published clinical data. J Ophthalmol 2014;2014:274780.
9. Ratra D, Dhupierr M. Retinal arterial occlusions in the young: Systemic associations in Indian population. Indian J Ophthalmol 2012;60:95-100.
10. Schmidt D. Comorbidities in combined retinal artery and vein occlusions. Eur J Med Res 2013;18:27.
11. Grzybowska A, Elikowski W, Gaca-Wysocka M. Cardiovascular risk factors in patients with combined central retinal vein occlusion and cilioretinal artery occlusion: Case report. Medicine (Baltimore) 2018;97:e2555.
12. Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res 2007;26:470-85.
13. AntS, Kwon SI. Neovascular glaucoma due to branch retinal vein occlusion combined with branch retinal artery occlusion. Korean J Ophthalmol 2013;27:64-7.
14. Aggio FB, Novelli FJ, Rosa EL, Nobrega MJ. Combined branch retinal vein and artery occlusion in toxoplasmosis. Arq Bras Oftalmol 2016;79:189-91.
15. Panchard SM. Combined central retinal vein and branch retinal artery occlusion in hyperhomocysteinaemia. BMJ Case Rep 2016;2016. doi: 10.1136/bcr-2016-218379.
16. Gaier ED, Miller JB, Loewenstein JJ. Combined central retinal vein occlusion and central retinal arterial obstruction with cilioretinal artery sparing. Ophthalmology 2017;124:576.
17. Coel S, Saurabh K, Roy R. Combined central retinal vein occlusion and branch retinal artery occlusion. Indian J Ophthalmol 2018;66:1862-3.
18. Dhawan A, Shukla D. Combined occlusion of branch retinal artery and vein secondary to preapillary arterial loops. Indian J Ophthalmol 2015;63:917-8.
19. Sinha S, Rau ATK, Kumar RV, Jayadev C, Vinekar A. Bilateral combined central retinal artery and vein occlusion in a 3-year-old child with nephrotic syndrome. Indian J Ophthalmol 2018;66:1498-501.
20. Bakri SS, Jomar D, Alsulaaiman SM, Abouamoh MA. Combined cilioretinal artery and hemi-retinal vein occlusion in Sturge Weber syndrome: Expanding the clinical spectrum. Saud J Ophthalmol 2018;32:234-7.
21. Malecés A, De Bats F, Kodjikian L, Denis P. Combined cilioretinal artery and central retinal vein occlusion complicating sleep apnea syndrome. J Fr Ophthalmol 2015;38:83-4.
22. Desai S, Rai N, Kulikarni P, Natarajan S. Combined CRVO with CRAO in a patient with protein C deficiency. Retin Cases Brief Rep 2014;8:145-9.
23. Hafidi Z, Handor H, Berradi S, Belmokhtar A, El Ouarradi H, Derrarr R, et al. Combined central retinal vein and cilioretinal artery occlusions in HELLP syndrome: A case report. J Fr Ophthalmol 2014;37:e105-6.
24. Domenech-Aracil N, Montero-Hernández J, Gracia-García A, Cervera-Tauleet E. Combined central retinal artery and vein occlusion secondary to cataract surgery in a patient with persistent hyaloid artery. Arch Esp Oftalmol 2014;89:1614.
25. Berkani Z, Ketoun Y, Belhadj A, Sidi K, Abbadi N, Bellatrache C, et al. Cilioretinal artery occlusion and central retinal vein occlusion complicating hyperhomocysteinemia: A case report. J Fr Ophthalmol 2013;36:e118-27.
26. Zhang L, Sun Y, Johnson MW, Richards JE, Morosi SE. Combined cilioretinal artery and central vein occlusions in juvenile glaucoma. Arch Ophthalmol 2011;129:1221-4.
27. Ozdamar Y, Gurlevik U, Acaroglu G, Teke MY, Zilelioglou O. Combined cilioretinal artery and partial central retinal vein occlusion in the postpartum period. Retin Cases Brief Rep 2010;4:99-101.
28. Sengupta S. Combined branch retinal artery and vein occlusion in hyperhomocysteinemia. JAMA Ophthalmol 2014;132:1255.
29. Lemos JA, Teixeira C, Carvalho R, Fernandes T. Combined central retinal artery and vein occlusion associated with factor V Leiden mutation and treated with hyperbaric oxygen. Case Rep Ophthalmol 2015;6:462-9.
30. Brazitikos PD, Pourmarous CJ, Othenin-Girard P, Borrut FX. Pathogenic mechanisms in combined cilioretinal artery and retinal vein occlusion: A reappraisal. Int Ophthalmol 1993;17:235-42.
31. Keyser BJ, Duker JS, Brown GC, Sergott RC, Bosley TM. Combined central retinal vein occlusion and cilioretinal artery occlusion associated with prolonged retinal arterial filling. Am J Ophthalmol 1994;117:308-13.
32. Olmos LC, Sayed MS, Moraczewski AL, Gedde SJ, Rosenfeld PJ, Shi W, et al. Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab. Eye (Lond) 2016;30:463-72.
33. Laouri M, Chen E, Looman M, Gallacher M. The burden of disease of retinal vein occlusion: Review of the literature. Eye (Lond) 2011;25:981-8.
34. Mason JO 3rd, Patel SA, Feist RM, Albert MA, Huisjing C, McGavin G, et al. Ocular neovascularization in eyes with a central retinal artery occlusion or a branch retinal artery occlusion. Clin Ophthalmol 2015;9:995-1000.
35. Hayreh SS, Rojas P, Podhajsky P, Montague P, Woolson RF. Ocular neovascularization with retinal vascular occlusion-III. Incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology 1983;90:488-506.